Identifying and treating bleeds while using novel haemophilia Tx
Research type
Research Study
Full title
How does the use of novel therapeutics with enhanced haemostatic protection influence symptoms, decision-making processes, and self-management when treating a bleed in people with haemophilia A? A qualitative study
IRAS ID
362080
Contact name
Paul McLaughlin
Contact email
Sponsor organisation
Royal Free London NHS Foundation Trust
Clinicaltrials.gov Identifier
10.17605/OSF.IO/UH89V, Center for Open Science
Duration of Study in the UK
1 years, 4 months, 1 days
Research summary
This is a qualitative research study to understand how, in an age of advanced therapeutic product use, haemophilia healthcare professionals and people with haemophilia A decide to treat a bleed. This study will use focus groups to collect data from participants 2 populations:
1. People with Haemophilia A who have taken treatment for a bleed in the past 12 months who:
- Are severe or moderate and use prophylaxis with extended half life FVIII
- Are severe and use prophylaxis with Emicizumab
- Are moderate or mild and have received FVIII CFC
- Have received Gene Therapy (FVIII)2. Healthcare professionals (HCPs) working in haemophilia who have assessed and treated a bleed in a person with haemophilia on enhanced haemostatic therapies in the past 12 months
Study data will be analysed using a Framework Analysis approach.
REC name
North East - York Research Ethics Committee
REC reference
26/NE/0117
Date of REC Opinion
25 Jun 2026
REC opinion
Further Information Favourable Opinion